Intervention

panitumumab

ClinicalTrials.gov intervention label

Clinical trials6

Recruiting1

Common conditions13

Lead sponsors shown5

Clinical trials

6 shown

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid TumorsNCT07094204 · 2025-07-25

Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung CancerNCT00979212 · 2011-02-01

Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast CancerNCT01009983 · 2010-03-01

First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung CancerNCT01038037 · 2010-01-01

Monoclonal Antibody Therapy in Treating Patients With Prostate CancerNCT00054574 · 2002-11-01

Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction CancerNCT00004879 · 2000-04-01

Common conditions

Colorectal Cancer2 Lung Cancer2 Prostate Cancer2 Breast Cancer1 Esophageal Cancer1 Kidney Cancer1 Non Small Cell Lung Cancer1 Non-Small-Cell Lung Cancer1 Pancreatic Cancer1 Pancreatic Ductal Adenocarcinoma1 Recurrent Breast Cancer1 Solid Tumor1 Stage IV Breast Cancer1

Leading sponsors

Jonsson Comprehensive Cancer Center2 Astellas Pharma Inc1 Radiation Therapy Oncology Group1 Vejle Hospital1 Wake Forest University Health Sciences1

Trial status mix

COMPLETED3

TERMINATED2

RECRUITING1

Phase mix

PHASE24

PHASE12

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.